Association Between Antithrombotic Medication Use After Bioprosthetic Aortic Valve Replacement and Outcomes in the Veterans Health Administration System

dc.contributor.authorBravata, Dawn M.
dc.contributor.authorCoffing, Jessica M.
dc.contributor.authorKansagara, Devan
dc.contributor.authorMyers, Jennifer
dc.contributor.authorMurphy, Lauren
dc.contributor.authorHomoya, Barbara J.
dc.contributor.authorPerkins, Anthony J.
dc.contributor.authorSnow, Kathryn
dc.contributor.authorQuin, Jacquelyn A.
dc.contributor.authorZhang, Ying
dc.contributor.authorMyers, Laura J.
dc.contributor.departmentMedicine, School of Medicineen_US
dc.date.accessioned2020-03-05T16:44:59Z
dc.date.available2020-03-05T16:44:59Z
dc.date.issued2018-12-26
dc.description.abstractIMPORTANCE: The recommendations about antithrombotic medication use after bioprosthetic aortic valve replacement (bAVR) vary. OBJECTIVES: To describe the post-bAVR antithrombotic medication practice across the Veterans Health Administration (VHA) and to assess the association between antithrombotic strategies and post-bAVR outcomes. DESIGN, SETTING, AND PARTICIPANTS: Retrospective cohort study. Multivariable modeling with propensity scores was conducted to adjust for differences in patient characteristics across the 3 most common antithrombotic medication strategies (aspirin plus warfarin sodium, aspirin only, and dual antiplatelets). Text mining of notes was used to identify the patients with bAVR (fiscal years 2005-2015). MAIN OUTCOMES AND MEASURES: This study used VHA and non-VHA outpatient pharmacy data and text notes to classify the following antithrombotic medications prescribed within 1 week after discharge from the bAVR hospitalization: aspirin plus warfarin, aspirin only, dual antiplatelets, no antithrombotics, other only, and warfarin only. The 90-day outcomes included all-cause mortality, thromboembolism risk, and bleeding events. Outcomes were identified using primary diagnosis codes from emergency department visits or hospital admissions. RESULTS: The cohort included 9060 veterans with bAVR at 47 facilities (mean [SD] age, 69.3 [8.8] years; 98.6% male). The number of bAVR procedures per year increased from 610 in fiscal year 2005 to 1072 in fiscal year 2015. The most commonly prescribed antithrombotic strategy was aspirin only (4240 [46.8%]), followed by aspirin plus warfarin (1638 [18.1%]), no antithrombotics (1451 [16.0%]), dual antiplatelets (1010 [11.1%]), warfarin only (439 [4.8%]), and other only (282 [3.1%]). Facility variation in antithrombotic prescription patterns was observed. During the 90-day post-bAVR period, adverse events were uncommon, including all-cause mortality in 127 (1.4%), thromboembolism risk in 142 (1.6%), and bleeding events in 149 (1.6%). No differences in 90-day mortality or thromboembolism were identified across the 3 antithrombotic medication groups in either the unadjusted or adjusted models. Patients receiving the combination of aspirin plus warfarin had higher odds of bleeding than patients receiving aspirin only in the unadjusted analysis (odds ratio, 2.58; 95% CI, 1.71-3.89) and after full risk adjustment (adjusted odds ratio, 1.92; 95% CI, 1.17-3.14). CONCLUSIONS AND RELEVANCE: These data demonstrate that bAVR procedures are increasingly being performed in VHA facilities and that aspirin only was the most commonly used antithrombotic medication strategy after bAVR. The risk-adjusted results suggest that the combination of aspirin plus warfarin does not improve either all-cause mortality or thromboembolism risk but increases the risk of bleeding events compared with aspirin only.en_US
dc.identifier.citationBravata, D. M., Coffing, J. M., Kansagara, D., Myers, J., Murphy, L., Homoya, B. J., ... & Myers, L. J. (2019). Association Between Antithrombotic Medication Use After Bioprosthetic Aortic Valve Replacement and Outcomes in the Veterans Health Administration System. JAMA surgery, 154(2), e184679-e184679. 10.1001/jamasurg.2018.4679en_US
dc.identifier.issn2168-6254en_US
dc.identifier.urihttps://hdl.handle.net/1805/22255
dc.language.isoen_USen_US
dc.publisherAmerican Medical Association (AMA)en_US
dc.relation.isversionof10.1001/jamasurg.2018.4679en_US
dc.relation.journalJAMA Surgeryen_US
dc.sourcePMCen_US
dc.subjectAntithrombotic Medicationen_US
dc.subjectBioprosthetic Aortic Valve Replacemenen_US
dc.subjectVeterans Health Administration Systemen_US
dc.titleAssociation Between Antithrombotic Medication Use After Bioprosthetic Aortic Valve Replacement and Outcomes in the Veterans Health Administration Systemen_US
dc.typeArticleen_US
ul.alternative.fulltexthttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6439666/en_US
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Association Between Antithrombotic Medication Use After Bioprosthetic Aortic Valve Replacement and Outcomes in the Veterans Health Administration System.pdf
Size:
433.82 KB
Format:
Adobe Portable Document Format
Description:
Main article
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description: